[go: up one dir, main page]

HK1116783A1 - - Google Patents

Info

Publication number
HK1116783A1
HK1116783A1 HK08107565.2A HK08107565A HK1116783A1 HK 1116783 A1 HK1116783 A1 HK 1116783A1 HK 08107565 A HK08107565 A HK 08107565A HK 1116783 A1 HK1116783 A1 HK 1116783A1
Authority
HK
Hong Kong
Application number
HK08107565.2A
Inventor
Paul W Manley
Wen-Chung Shieh
Paul Allen Sutton
Piotr H Karpinski
Raeann Wu
Stephanie Monnier
Joerg Brozio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37451227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1116783(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1116783A1 publication Critical patent/HK1116783A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK08107565.2A 2005-07-20 2008-07-09 HK1116783A1 (xx)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70140505P 2005-07-20 2005-07-20
US71621405P 2005-09-12 2005-09-12
PCT/US2006/027875 WO2007015870A2 (en) 2005-07-20 2006-07-18 Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Publications (1)

Publication Number Publication Date
HK1116783A1 true HK1116783A1 (xx) 2009-01-02

Family

ID=37451227

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08107565.2A HK1116783A1 (xx) 2005-07-20 2008-07-09

Country Status (43)

Country Link
US (4) US8343984B2 (xx)
EP (5) EP2535337B1 (xx)
JP (3) JP5289948B2 (xx)
KR (3) KR101651288B1 (xx)
CN (2) CN103804356A (xx)
AR (1) AR054846A1 (xx)
AU (3) AU2006276204A1 (xx)
BR (1) BRPI0613615B1 (xx)
CA (1) CA2614334C (xx)
CR (1) CR9657A (xx)
CU (1) CU23916B1 (xx)
CY (2) CY1113076T1 (xx)
DK (2) DK2284167T4 (xx)
EA (2) EA016856B1 (xx)
EC (1) ECSP088119A (xx)
ES (3) ES2648288T3 (xx)
GE (1) GEP20115302B (xx)
GT (1) GT200600315A (xx)
HK (1) HK1116783A1 (xx)
HN (1) HN2008000311A (xx)
HR (2) HRP20120573T1 (xx)
HU (1) HUE031791T2 (xx)
IL (2) IL188189A0 (xx)
JO (1) JO3308B1 (xx)
LT (1) LT2284167T (xx)
MA (1) MA29626B1 (xx)
MX (1) MX2008000899A (xx)
MY (1) MY148554A (xx)
NI (1) NI200800017A (xx)
NO (1) NO341930B1 (xx)
NZ (1) NZ564409A (xx)
PE (1) PE20070214A1 (xx)
PH (1) PH12013501590A1 (xx)
PL (2) PL1912973T3 (xx)
PT (2) PT1912973E (xx)
RS (1) RS55929B2 (xx)
SG (1) SG163620A1 (xx)
SI (2) SI2284167T2 (xx)
SM (1) SMAP200800011A (xx)
TN (1) TNSN08029A1 (xx)
TW (1) TWI406661B (xx)
UA (1) UA94234C2 (xx)
WO (1) WO2007015870A2 (xx)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
AU2007235976A1 (en) * 2006-04-07 2007-10-18 Novartis Ag Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
JP2011507880A (ja) * 2007-12-21 2011-03-10 ノバルティス アーゲー 慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤
WO2010009402A2 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
PL2262793T3 (pl) * 2008-11-05 2013-01-31 Teva Pharma Formy krystaliczne nilotynibu HCL
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
RU2011140404A (ru) 2009-03-06 2013-04-20 Новартис Аг Применение производных пиримидиламинобензамида для лечения нарушений, опосредованных киназой, содержащей мотив лейциновой "молнии" и стерильный альфа мотив (zak)
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
KR101853596B1 (ko) 2009-10-23 2018-04-30 노파르티스 아게 Ｂｃｒ-ａｂｌ, ｃ-ｋｉｔ, ｄｄｒ1, ｄｄｒ2 또는 ｐｄｇｆ-ｒ 키나제 활성에 의해 매개된 증식성 장애 및 다른 병적 상태의 치료 방법
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
WO2011086541A1 (en) * 2010-01-15 2011-07-21 Generics [Uk] Limited Novel polymorph of nilotinib monohydrochloride monohydrate
JP2013525296A (ja) 2010-04-16 2013-06-20 ノバルティス アーゲー 内分泌療法抵抗性乳癌の処置
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
ES2555263T3 (es) 2010-06-21 2015-12-30 Teva Pharmaceutical Industries Ltd. Sales de Nilotinib y formas cristalinas de las mismas
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
IN2010CH03577A (xx) * 2010-11-26 2012-07-20 Hetero Research Foundation
AR086913A1 (es) 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
CA2853095A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
KR20140093230A (ko) 2011-11-14 2014-07-25 노파르티스 아게 즉시 방출 4-메틸-3-[[4-(3-피리디닐)-2-피리미디닐]아미노]-n-[5-(4-메틸-1h-이미다졸-1-일)-3-(트리플루오로메틸)페닐] 벤즈아미드 제제
ES2564969T3 (es) * 2012-02-09 2016-03-30 Natco Pharma Limited Proceso para la preparación de clorhidrato de nilotinib
GB2514285B (en) 2012-02-13 2018-07-18 Grindeks Jsc Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
CA2878251A1 (en) 2012-07-11 2014-01-16 Novartis Ag Method of treating gastrointestinal stromal tumors
EP2906554A4 (en) * 2012-10-15 2016-06-29 Apotex Inc SOLID FORMS OF NILOTINIB HYDROCHLORIDE
AU2013333953B2 (en) * 2012-10-19 2017-08-31 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
HUE040434T2 (hu) * 2013-02-21 2019-03-28 Pfizer Szelektív CDK4/6 inhibitor szilárd alakjai
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
JP2016522182A (ja) 2013-04-24 2016-07-28 ドクター レディズ ラボラトリーズ リミテッド ニロチニブ塩酸塩の多形形態
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
WO2016020891A1 (en) 2014-08-08 2016-02-11 Dr. Reddy’S Laboratories Limited Process for the preparation of polymorphic forms of nilotinib
WO2016058081A1 (en) * 2014-10-16 2016-04-21 Apotex Inc. Solid forms of nilotinib hydrochloride
SI3408264T1 (sl) 2016-01-26 2020-07-31 Farma Grs, D.O.O. Nilotinibijev dinitrat (V) in njegove kristalne oblike
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
SI3430004T1 (sl) 2016-03-14 2021-03-31 Pliva Hrvatska D.O.O. Trdne oblike soli nilotiniba
CN106496193A (zh) * 2016-09-13 2017-03-15 福格森（武汉）生物科技股份有限公司 一种高纯度尼罗替尼的制备方法
EP3404025B1 (en) 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法
US12065426B2 (en) 2018-11-05 2024-08-20 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
AU2021212258A1 (en) 2020-01-31 2022-09-29 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
CN116635015A (zh) 2020-09-29 2023-08-22 深圳市药欣生物科技有限公司 药物组合物
EP4355306A1 (en) 2021-06-19 2024-04-24 Helm AG Granulate composition comprising nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
CN116102540B (zh) * 2023-01-05 2025-03-25 浙江工业大学 两种尼洛替尼游离碱新晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701406A (en) 1901-07-16 1902-06-03 Thomas K Jones Cut-off-valve mechanism.
US701405A (en) 1902-02-17 1902-06-03 Archibald White Maconochie Ejecting device for stamping-machines.
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
CN101693031A (zh) * 2003-11-18 2010-04-14 诺瓦提斯公司 Kit突变形式的抑制剂
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Also Published As

Publication number Publication date
CN102358736A (zh) 2012-02-22
EP2543665A3 (en) 2013-05-29
JP2013018789A (ja) 2013-01-31
IL188189A0 (en) 2008-03-20
CY1113076T1 (el) 2016-04-13
RS55929B1 (sr) 2017-09-29
CU23916B1 (es) 2013-07-31
TW200740793A (en) 2007-11-01
BRPI0613615A2 (pt) 2011-01-18
SMP200800011B (it) 2008-02-27
DK2284167T3 (en) 2017-05-01
NZ564409A (en) 2011-07-29
EP2284168A2 (en) 2011-02-16
NO341930B1 (no) 2018-02-19
EP2284167A2 (en) 2011-02-16
US20140343087A1 (en) 2014-11-20
PT1912973E (pt) 2012-09-03
JP2009502795A (ja) 2009-01-29
ECSP088119A (es) 2008-02-20
HRP20170634T1 (hr) 2017-06-30
JO3308B1 (ar) 2018-09-16
DK2284167T4 (da) 2020-03-02
NI200800017A (es) 2009-03-03
HUE031791T2 (en) 2017-08-28
EP2535337A1 (en) 2012-12-19
AU2006276204A1 (en) 2007-02-08
SMAP200800011A (it) 2008-02-27
US20130165465A1 (en) 2013-06-27
EA016856B1 (ru) 2012-08-30
TNSN08029A1 (en) 2009-07-14
JP5289948B2 (ja) 2013-09-11
KR20080027853A (ko) 2008-03-28
CU20080006A7 (es) 2011-02-24
BRPI0613615B1 (pt) 2022-02-08
PL2284167T5 (pl) 2020-07-27
WO2007015870A2 (en) 2007-02-08
US8829015B2 (en) 2014-09-09
GT200600315A (es) 2007-03-19
EP2535337B1 (en) 2017-08-23
AU2011202047A1 (en) 2011-05-26
AR054846A1 (es) 2007-07-18
RS55929B2 (sr) 2020-12-31
PH12013501590A1 (en) 2015-09-21
EP2284167B2 (en) 2019-11-27
NO20080820L (no) 2008-04-15
MA29626B1 (fr) 2008-07-01
ES2648288T3 (es) 2017-12-29
AU2012201453B2 (en) 2013-09-05
SI2284167T2 (sl) 2020-03-31
WO2007015870A3 (en) 2007-06-07
DK1912973T3 (da) 2012-07-23
GEP20115302B (en) 2011-10-10
LT2284167T (lt) 2017-04-25
HRP20170634T4 (hr) 2020-02-07
ES2386974T3 (es) 2012-09-10
CN103804356A (zh) 2014-05-21
US20130023548A1 (en) 2013-01-24
AU2012201453A1 (en) 2012-04-05
EP1912973B1 (en) 2012-06-13
SI2284167T1 (sl) 2017-05-31
PL1912973T3 (pl) 2012-09-28
MY148554A (en) 2013-04-30
CA2614334A1 (en) 2007-02-08
KR101651288B1 (ko) 2016-08-25
ES2623608T5 (es) 2020-06-18
HRP20120573T1 (hr) 2012-08-31
PT2284167T (pt) 2017-05-15
CY1119624T1 (el) 2018-04-04
KR20130077915A (ko) 2013-07-09
EP2543665A2 (en) 2013-01-09
JP2014221831A (ja) 2014-11-27
EA200800201A1 (ru) 2008-06-30
EA201000145A1 (ru) 2010-06-30
EP1912973A2 (en) 2008-04-23
AU2012201453C1 (en) 2024-05-23
US8343984B2 (en) 2013-01-01
CA2614334C (en) 2015-04-21
EP2284168A3 (en) 2011-04-13
UA94234C2 (xx) 2011-04-26
JP5798101B2 (ja) 2015-10-21
SG163620A1 (en) 2010-08-30
KR20130085444A (ko) 2013-07-29
EP2284167B1 (en) 2017-02-01
MX2008000899A (es) 2008-03-18
EA013464B1 (ru) 2010-04-30
SI1912973T1 (sl) 2012-08-31
TWI406661B (zh) 2013-09-01
EP2284167A3 (en) 2011-03-02
US20080269269A1 (en) 2008-10-30
CR9657A (es) 2008-04-16
ES2623608T3 (es) 2017-07-11
US8415363B2 (en) 2013-04-09
PE20070214A1 (es) 2007-04-02
HN2008000311A (es) 2011-01-24
PL2284167T3 (pl) 2017-07-31
IL214659A0 (en) 2011-09-27

Similar Documents

Publication Publication Date Title
BRPI0601358B8 (pt) Aplicador de clipe cirúrgico
BR122017004709A2 (xx)
BRPI0609157A8 (xx)
BRPI0608519A2 (xx)
BR122020005056A2 (xx)
BR122016029989A2 (xx)
DE602006007870D1 (xx)
JP2006352822A5 (xx)
JP2006228435A5 (xx)
JP2006324922A5 (xx)
JP2006293805A5 (xx)
BRPI0618215B8 (xx)
JP2006263391A5 (xx)
BY2237U (xx)
JP2006345467A5 (xx)
CN105122969C (xx)
CN300726004S (zh) 鞋帮
CN300726008S (zh) 鞋帮
CN300726699S (zh) 调料瓶套装(d)
CN300725997S (zh) 鞋帮
CN300725996S (zh) 鞋帮
CN300725995S (zh) 鞋帮
CN300725994S (zh) 鞋底
CN300749517S (zh) 浴室壁橱
CN300725993S (zh) 鞋帮